Valuation Negotiated Down

Investors accept the strategic importance of Isomorphic but resist the $40 billion to $50 billion price after comparing it with public biotech and software multiples. The company still raises capital, but the discount tempers enthusiasm for AI drug-discovery peers.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.